VEEV Veeva Systems Inc.

$163.76▼ -2.34% Healthcare Other Last sync: just now Syncing
Key Metrics & Fundamentals
Market Cap
$26.60B
P/E Ratio
29.8
Div Yield
–%
52W Range
148.05 - 310.50
% vs 50 MA
1.02%
% vs 200 MA
-24.59%
RSI-14
49.1
MACD Histogram
+0.3900
Beta (1Y vs SPY)
0.70
Free Cash Flow
$1.13B
Gross Rev
$882.95M
Gross Profit
$662.02M
EBITDA
$284.70M
COGS
$220.92M
Operating Exp
$388.91M
Operating Income
$273.11M
EBIT
$273.11M
Pretax Income
$347.53M
Net Income
$260.94M
EPS (Diluted)
1.57
Price & Volume History
Volume (M)
Financial Overview - Income Statement Quarterly
AI Analysis
Generated May 27, 8:05 PM
Company Overview

Veeva Systems is a leading provider of cloud-based software solutions specifically tailored for the global life sciences industry. It offers a comprehensive suite of applications for customer relationship management, content management, and regulatory compliance, establishing a critical infrastructure role for pharmaceutical and biotech companies.

Bull Case
  • Dominant market position in providing specialized cloud software for the highly regulated life sciences sector, creating high switching costs.
  • Strong recurring revenue model from its subscription-based software services, providing predictable cash flows and high customer retention.
  • Significant addressable market driven by ongoing R&D investments, increasing regulatory complexity, and digital transformation within healthcare.
  • Current price represents a substantial discount from its 52-week high, potentially offering an attractive entry point for long-term investors if growth prospects remain robust.
Bear Case
  • The stock is in a significant downtrend, trading well below its 50-day and 200-day moving averages, indicating strong bearish momentum.
  • Valuation, despite the price drop, still carries a P/E ratio of 29.2, which may be considered high if growth rates decelerate or market sentiment shifts.
  • Potential for increased competition from larger enterprise software providers or new specialized entrants in the life sciences technology space.
  • Reliance on the cyclical and regulatory-dependent pharmaceutical and biotechnology industries, which can influence customer spending and growth.
Recent Performance

Veeva Systems has experienced a substantial decline, trading near its 52-week low and down nearly 49% from its peak. The stock is firmly entrenched in a downtrend, trading significantly below both its 50-day and 200-day moving averages. The RSI-14 at 43.8 suggests the stock is not yet oversold, implying potential for further downward movement or continued consolidation before a reversal.

AI-generated analysis is for informational purposes only and does not constitute financial advice.

Not Financial Advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making any investment decisions. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙